Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Benavides

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Substance Abuse : Research and Treatment|May 10, 2019
Influence of Tobacco Smoke Exposure on the Protein Expression of α7 and α4 Nicotinic Acetylcholine Receptors in Squamous Cell Carcinoma Tumors of the Upper Aerodigestive Tract (Out of the Larynx)Bertha B Montaño-Velázquez, Juan C Benavides Méndez, Francisco J García-Vázquez, et al.
Hormone Research in Paediatrics|August 28, 2025
Team Based Pediatric Type 1 Diabetes Care in the US: Current Practices and Sustainability ConcernsKsenia N Tonyushkina, Christine A March, Risa M Wolf, et al.
British Poultry Science|June 18, 2021
Comparative analysis of the morphology, chemistry and structure of the tibiotarsus, humerus and keel bones in laying hensC Benavides-Reyes, A B Rodriguez-Navarro, H A McCormack, et al.
Cancer|August 30, 2008
Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Jarrod P Holmes, Jeremy D Gates, Linda C Benavides, et al.
Expert Review of Vaccines|February 22, 2011
Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccinesLinda C Benavides, Alan K Sears, Jeremy D Gates, et al.
Cancer|October 13, 2011
Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Elizabeth A Mittendorf, Guy T Clifton, Jarrod P Holmes, et al.
Human Vaccines|April 26, 2008
Monitoring circulating tumor cells in cancer vaccine trialsJ D Gates, L C Benavides, A Stojadinovic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2009
The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02Linda C Benavides, Jeremy D Gates, Mark G Carmichael, et al.
Journal of the American College of Surgeons|February 21, 2009
Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patientsJeremy D Gates, Mark G Carmichael, Linda C Benavides, et al.
Animal : an International Journal of Animal Bioscience|March 5, 2025
Genomic prediction of bone strength in laying hens using different sources of informationM Sallam, H Wall, P W Wilson, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Substance Abuse : Research and Treatment|May 10, 2019
Influence of Tobacco Smoke Exposure on the Protein Expression of α7 and α4 Nicotinic Acetylcholine Receptors in Squamous Cell Carcinoma Tumors of the Upper Aerodigestive Tract (Out of the Larynx)Bertha B Montaño-Velázquez, Juan C Benavides Méndez, Francisco J García-Vázquez, et al.
Hormone Research in Paediatrics|August 28, 2025
Team Based Pediatric Type 1 Diabetes Care in the US: Current Practices and Sustainability ConcernsKsenia N Tonyushkina, Christine A March, Risa M Wolf, et al.
British Poultry Science|June 18, 2021
Comparative analysis of the morphology, chemistry and structure of the tibiotarsus, humerus and keel bones in laying hensC Benavides-Reyes, A B Rodriguez-Navarro, H A McCormack, et al.
Cancer|August 30, 2008
Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Jarrod P Holmes, Jeremy D Gates, Linda C Benavides, et al.
Expert Review of Vaccines|February 22, 2011
Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccinesLinda C Benavides, Alan K Sears, Jeremy D Gates, et al.
Cancer|October 13, 2011
Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Elizabeth A Mittendorf, Guy T Clifton, Jarrod P Holmes, et al.
Human Vaccines|April 26, 2008
Monitoring circulating tumor cells in cancer vaccine trialsJ D Gates, L C Benavides, A Stojadinovic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2009
The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02Linda C Benavides, Jeremy D Gates, Mark G Carmichael, et al.
Journal of the American College of Surgeons|February 21, 2009
Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patientsJeremy D Gates, Mark G Carmichael, Linda C Benavides, et al.
Animal : an International Journal of Animal Bioscience|March 5, 2025
Genomic prediction of bone strength in laying hens using different sources of informationM Sallam, H Wall, P W Wilson, et al.
Pageof 6